newsInterleukin-6 inhibitors improve outcomes for COVID-19 patients in study5 August 2020 | By Victoria Rees (European Pharmaceutical Review)Researchers have shown that symptoms in patients experiencing severe COVID-19 improved when given either sarilumab or tocilizumab, interleukin-6 inhibitors.